Using mass measurements in tracer studies-a systematic approach to efficient modeling

Metabolism: Clinical and Experimental

Volumn 57, Issue 8, 2008, Pages 1078-1087

  Ramakrishnan, Rajasekhar ^a   Ramakrishnan, Janak D ^b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MEASUREMENT; PRIORITY JOURNAL;

APOLIPOPROTEINS B; KINETICS; LIPOPROTEINS; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MATHEMATICAL COMPUTING; MODELS, BIOLOGICAL; RADIOACTIVE TRACERS;

EID: 47149092856     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.03.011     Document Type: Article

References (52)

1. Rescigno A., and Segre G. Drug and tracer kinetics (1966), Waltham, Blaisdell
2. Neer R., Berman M., Fisher L., et al. Multicompartmental analysis of calcium kinetics in normal adult males. J Clin Invest 46 (1967) 1364-1379
3. Shames D.M., Berman M., and Segal S. Effects of thyroid disease on glucose oxidative metabolism in man. A compartmental model analysis. J Clin Invest 50 (1971) 627-641
4. Goodman D.S., Smith F.R., Seplowitz A.H., et al. Prediction of the parameters of whole body cholesterol metabolism in humans. J Lipid Res 21 (1980) 699-713
5. Berman M. Kinetic analysis and modeling: theory and applications to lipoproteins. In: Berman M., Grundy S.M., and Howard B.V. (Eds). Lipoprotein kinetics and modeling (1982), Academic Press, New York 3-36
6. Cobelli C., and Foster D.M. Compartmental models: theory and practice using the SAAM II software system. Adv Exp Med Biol 445 (1998) 79-101
7. Barrett P.H.R., Bell B.M., Cobelli C., et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 47 (1998) 484-492
8. Packard C.J., Shepherd J., Joerns S., et al. Apolipoprotein B metabolism in normal, type IV, and type V hyperlipoproteinemic subjects. Metabolism 29 (1980) 213-222
9. Arad Y., Ramakrishnan R., and Ginsberg H.N. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 31 (1990) 567-582
10. Chan D.C., Watts G.F., Redgrave T.G., et al. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 51 (2002) 1041-1046
11. Zheng C., Ikewaki K., Walsh B.W., et al. Rapid turnover of apolipoprotein CIII containing triglyceride-rich lipoproteins contributing to formation of LDL subfractions. J Lipid Res 48 (2007) 1190-1203
12. Demant T., Packard C.J., Demmelmair H., et al. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am J Physiol-Endocrinol Metab 270 (1996) E1022-E1036
13. Adiels M., Packard C.J., Caslake M.J., et al. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 46 (2005) 58-67
14. Cohn J.S., Wagner D.A., Cohn S.D., et al. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 85 (1990) 804-811
15. Lichtenstein A.H., Hachey D., Millar J.S., et al. Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5-2H3]leucine. J Lipid Res 33 (1992) 907-914
16. Welty F.K., Lichtenstein A.H., Barrett P.H.R., et al. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 24 (2004) 1703-1707
17. Walsh B.W., and Sacks F.M. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest 91 (1993) 2126-2132
18. Tomiyasu K., Walsh B.W., Ikewaki K., et al. Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol 21 (2001) 1494-1500
19. Welty F.K., Lichtenstein A.H., Barrett P.H.R., et al. Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. Arterioscler Thromb Vasc Biol 17 (1997) 881-888
20. Pont F., Duvillard L., Verges B., et al. Development of compartmental models in stable-isotope experiments-application to lipid metabolism. Arterioscler Thromb Vasc Biol 18 (1998) 853-860
21. Chan D.C., Barrett P.H.R., and Watts G.F. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. Clin Sci 107 (2004) 221-232
22. Foster D.M., Barrett P.H.R., Toffolo G., et al. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable-isotope data. J Lipid Res 34 (1993) 2193-2205
23. Demant T., Packard C.J., Stewart P., et al. Sensitive mass-spectrometry techniques for measuring metabolism of human apolipoprotein-B in-vivo. Clin Chem 40 (1994) 1825-1827
24. Barrett P.H.R., and Foster D.M. Design and analysis of lipid tracer kinetic studies. Curr Opin Lipidol 7 (1996) 143-148
25. Cobelli C., and Caumo A. Using what is accessible to measure that which is not: necessity of model of system. Metab-Clin Exp 47 (1998) 1009-1035
26. Barrett P.H.R., Chan D.C., and Watts G.F. Design and analysis of lipoprotein tracer kinetics studies in humans. J Lipid Res 47 (2006) 1607-1619
27. Brownell G.L., Berman M., and Robertson J.S. Nomenclature for tracer kinetics. Int J Appl Radiat Isot 19 (1968) 249-262
28. Nagashima K., Lopez C., Donovan D., et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115 (2005) 1323-1332
29. DiStefano 3rd J.J. Complete parameter bounds and quasiidentifiability conditions for a class of unidentifiable linear systems. Math Biosci 65 (1983) 51-68
30. Hearon J.Z. Theorems on linear systems. Ann N Y Acad Sci 108 (1963) 36-68
31. Himmelblau D.M., and Bischoff K.B. Process analysis and simulation-deterministic systems (1968), Wiley, New York
32. Jacquez J.A. Compartmental analysis in biology and medicine (1985), University of Michigan, Ann Arbor
33. Berman M., and Schoenfeld R. Invariants in experimental data on linear kinetics and the formulation of models. J Appl Phys 27 (1956) 1361-1370
34. Walter E., and Lecourtier Y. Unidentifiable compartmental models: what to do?. Math Biosci 56 (1981) 1-25
35. Ramakrishnan R. An application of Berman's work on pool-model invariants in analyzing indistinguishable models for whole-body cholesterol metabolism. Math Biosci 72 (1984) 373-385
36. Vajda S. Structural equivalence and exhaustive compartmental modeling. Math Biosci 69 (1984) 57-75
37. Chapman M.J., and Godfrey K.R. Some extensions to the exhaustive modelling approach to structural identifiability. Math Biosci 77 (1985) 305-323
38. Hearon J.Z. The washout curve in tracer kinetics. Math Biosci 3 (1968) 31-39
39. Hearon J.Z. Interpretation of tracer data. Biophys J 9 (1969) 1363-1370
40. Hearon J.Z. A note on open linear systems. Bull Math Biol 36 (1974) 97-99
41. Perl W., Lassen N.A., and Effros R.M. Matrix proof of flow, volume and mean transit time theorems for regional and compartmental systems. Bull Math Biol 37 (1975) 573-588
42. Covell D.G., Berman M., and Delisi C. Mean residence time-theoretical development, experimental determination, and practical use in tracer analysis. Math Biosci 72 (1984) 213-244
43. Ramakrishnan R., Leonard E.F., and Dell R.B. A proof of the occupancy principle and the mean transit time theorem for compartmental models. Math Biosci 68 (1984) 121-136
44. DiStefano 3rd J.J., Chen B.C., and Landaw E.M. Pool size and mass flux bounds and quasiidentifiability relations for catenary models. Math Biosci 88 (1988) 1-14
45. Welty F.K., Lichtenstein A.H., Barrett P.H.R., et al. Human apolipoprotein (apo) B-48 and apoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol 19 (1999) 2966-2974
46. Barrett P.H.R., and Watts G.F. Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions. Curr Opin Lipidol 14 (2003) 61-68
47. Lundahl B., Skoglund-Andersson C., Caslake M., et al. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles. Am J Physiol-Endocrinol Metab 290 (2006) E739-E745
48. Tremblay A.J., Lamarche B., Cohn J.S., et al. Effect of ezetimibe on the in vivo kinetics of ApoB-48 and ApoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol 26 (2006) 1101-1106
49. Malmstrom R., Packard C.J., Caslake M., et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40 (1997) 454-462
50. Malmstrom R., Packard C.J., Watson T.D.G., et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17 (1997) 1454-1464
51. Malmstrom R., Packard C.J., Caslake M., et al. Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects. Atherosclerosis 146 (1999) 381-390
52. de Roos B., Caslake M.J., Stalenhoef A.F.H., et al. The coffee diterpene cafestol increases plasma triacylglycerol by increasing the production rate of large VLDL apolipoprotein B in healthy normolipidemic subjects. Am J Clin Nutr 73 (2001) 45-52